| Literature DB >> 34225678 |
Ziyuan Huang1,2, Bo Chen1,2, Ying Zhou1,2, Yan Liang1,2, Wenxian Qiu1,2, Yinqiu Lv1,2, Xiaokai Ding1,2, Ji Zhang3,4, Chaosheng Chen5,6.
Abstract
BACKGROUND: The clinicopathological and prognostic features of IgA-dominant postinfectious glomerulonephritis and its difference from the primary IgA nephropathy remains to be investigated.Entities:
Keywords: Clincopathology; Glomerulonephritis; IgA-dominant postinfectious glomerulonephritis; Kidney disease; Prognosis
Mesh:
Substances:
Year: 2021 PMID: 34225678 PMCID: PMC8256496 DOI: 10.1186/s12882-021-02462-3
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
IgA-dominant postinfectious glomerulonephritis: demographic and history
| Patient | Sex | Age | Pathogen | Infection site | The interval between onset of infections and nephritis | Antibiotics | Complication |
|---|---|---|---|---|---|---|---|
| 1 | M | 54 | S.aureus | Skin | ND | LZD | LC; Foot injury; HTN |
| 2 | M | 76 | S.aureus | Skin | ND | OX | ND |
| 3 | M | 64 | ND | ND | ND | ND | HTN; DM |
| 4 | F | 57 | ND | lung | ND | PRL | NAFLD |
| 5 | M | 80 | ND | Skin | 2 months | RL | HTN; Fracture |
| 6 | M | 62 | M.tuberculosis | lung | ND | PRL | HTN; NAFLD |
| 7 | F | 54 | M.catarrhalis | URT | ND | SCF | HTN; |
| 8 | F | 19 | ND | URT | < 2days | CEC; PRL | ND |
| 9 | F | 34 | UU + M.hominis | UT | ND | ND | ND |
| 10 | M | 49 | ND | ND | ND | ND | ND |
| 11 | F | 27 | ND | ND | ND | ND | ND |
| 12 | F | 46 | ND | URT | ND | ND | HTN; Myoma uterus |
| 13 | F | 31 | ND | ND | ND | ND | ND |
| 14 | M | 58 | ND | lung | 2weeks | PRL; MEM | HTN; CD; HBV |
| 15 | F | 74 | E.coli | URT | ND | CZO | HTN; DM |
| 16 | M | 58 | ND | ND | ND | ND | HTN |
| 17 | F | 61 | UU | URT | ND | AZM | HTN |
| 18 | F | 45 | ND | ND | ND | ND | HTN |
| 19 | F | 43 | ND | lung | ND | CZO; AZM | HTN; DM |
| 20 | M | 26 | ND | ND | ND | ND | HTN |
| 21 | F | 19 | H.parainfluenzae | URT | ND | ND | ND |
| 22 | F | 43 | ND | ND | ND | ND | HTN; HBV |
| 23 | F | 27 | ND | URT | < 1 day | SCF | ND |
| 24 | F | 38 | ND | ND | ND | ND | Sacroilitis; NAFLD |
| 25 | M | 36 | ND | ND | ND | ND | ND |
| 26 | M | 20 | ND | UT | 4days | CRO | ALF |
| 27 | F | 42 | ND | UT | ND | ND | ND |
| 28 | M | 50 | ND | ND | ND | ND | Fracture |
| 29 | F | 31 | ND | ND | ND | ND | ND |
| 30 | F | 30 | ND | URT | 1 day | CEC | Acute tonsillitis |
| 31 | M | 61 | ND | ND | ND | ND | HTN |
| 32 | F | 36 | ND | ND | ND | ND | ND |
| 33 | F | 21 | ND | Skin | ND | ND | ND |
| 34 | M | 27 | ND | GIT | < 1 day | ND | ND |
| 35 | M | 50 | ND | ND | ND | ND | ND |
| 36 | F | 42 | ND | UT | ND | LEV | ND |
| 37 | F | 21 | ND | ND | ND | ND | HBV |
| 38 | F | 70 | ND | UT | < 1 day | MEM; SCF | NAFLD |
| 39 | F | 35 | ND | UT | ND | ND | ND |
| 40 | F | 28 | ND | ND | ND | ND | ND |
| 41 | M | 34 | E.coli | UT | ND | LEV | ND |
| 42 | F | 33 | ND | URT | 1 | ZOX | Bulbar ulcers |
| 43 | F | 25 | ND | URT | < 10days | ND | ND |
| 44 | M | 38 | ND | ND | ND | ND | HTN |
| 45 | M | 35 | ND | URT | ND | ND | HBV |
| 46 | M | 45 | ND | UT | ND | SCF;CEC | HBV |
| 47 | M | 60 | ND | GIT | ND | ND | HTN; HBV |
| 48 | M | 25 | S. salivarius | abdominal | ND | VCA; MXF | HTN |
| 49 | F | 52 | ND | GIT | ND | ND | HBV; Myoma uterus |
| 50 | F | 49 | ND | ND | ND | ND | HTN; DM |
Sex: M male, F female Pathogen: E.coli escherichia coli, H.parainfluenzae Hemophilus parainfluenzae, M.catarrhalis moraxella catarrhalis, M.hominis mycoplasma hominis, M.tuberculosis mycobacterium tuberculosis, S.aureus staphylococcus aureus, S. salivarius staphylococcus salivarius, UU Ureaplasma Urealyticum
Infection site: GIT gastrointestinal tract, URT upper respiratory tract, UT urinary tract
Antibiotics: AZM azithromycin, CEC cefaclor, CRO ceftriaxone, CZO cefazolin, LEV levofloxacin, LZD linezolid, MEM meropenem, MXF moxifloxacin, OX oxacillin, PRL piperacillin, RL Sulfamethoxazole, SCF Cefperazone sulbactam, VCA vancomycin, ZOX cefuroxime
Complications: ALF abnormal liver function, CD crohn disease, DM diabetes mellitus, LC live cirrhosis, HTN hypertesion, HBV hepatitis B, NAFLD non-alcoholic fatty liver disease, ND no data
IgA-dominant postinfectious glomerulonephritis: summary of demographic and history
| Total (N = 50) | |
|---|---|
| Sex | |
| F | 29 (58.0 %) |
| M | 21 (42.0 %) |
| Pathogen | |
| E.coli | 2 (4.0 %) |
| H.Parainfluenzae | 1 (2.0 %) |
| M.catarrhalis | 1 (2.0 %) |
| M.Tuberculosis | 1 (2.0 %) |
| UU | 2 (4.0 %) |
| M.Hominis | 1 (2.0 %) |
| S.Aureus | 2 (4.0 %) |
| S.Salivarius | 1 (2.0 %) |
| ND | 40 (80.0 %) |
| Infection site | |
| Abdominal | 1 (2.0 %) |
| GIT | 3 (6.0 %) |
| Lung | 4 (8.0 %) |
| Skin | 4 (8.0 %) |
| URT | 9 (18.0 %) |
| UT | 10 (20.0 %) |
| ND | 19 (38.0 %) |
| The interval of onset of infections and nephritis | |
| <3days | 6 (12.0 %) |
| 3days-2weeks | 3(6.0 %) |
| >2weeks | 1 (2.0 %) |
| ND | 40 (80.0 %) |
| Complication | |
| Acute Tonsillitis | 1 (2.0 %) |
| ALF | 1 (2.0 %) |
| Bulbar Ulcers | 1 (2.0 %) |
| CD | 1 (2.0 %) |
| DM | 4 (8.0 %) |
| Foot Injury | 1 (2.0 %) |
| Fracture | 2 (4.0 %) |
| HBV | 7 (14.0 %) |
| HTN | 18 (36.0 %) |
| LC | 1 (2.0 %) |
| Myoma Uterus | 2 (4.0 %) |
| NAFLD | 4 (8.0 %) |
| Sacroilitis | 1 (2.0 %) |
| ND | 20 (40.0 %) |
Sex: M male, F female
Pathogen: E.coli escherichia coli, H.parainfluenzae Hemophilus parainfluenzae, M.catarrhalis moraxella catarrhalis, M.hominis mycoplasma hominis, M.tuberculosis mycobacterium tuberculosis, S.aureus staphylococcus aureus, S. salivarius staphylococcus salivarius, UU Ureaplasma Urealyticum
Infection site: GIT gastrointestinal tract, URT upper respiratory tract, UT urinary tract
Complications: ALF abnormal liver function, CD crohn disease, DM diabetes mellitus, LC live cirrhosis, HTN hypertesion,HBV hepatitis B, NAFLD non-alcoholic fatty liver disease, ND no data
IgA-dominant postinfectious glomerulonephritis: Light microscopy
| Statistical result | |
|---|---|
| Total = 50 | |
| Number of glomeruli(mean) | 22.2 |
| Global sclerosis (mean) | 3.3 |
| Histological pattern | |
| Acute endocapillary proliferative glomerulonephritis(%) | 40(80 %) |
| Mesangial proliferative glomerulonephritis(%) | 6(12.0 %) |
| Membrane proliferative glomerulonephritis(%) | 3(6.0 %) |
| Crescent glomerulonephritis(%) | 1(2.0 %) |
| Mesangial hypercellularity(%) | 47(94.0 %) |
| Mesangial matrix expansion(%) | 42(84.0 %) |
| Endocapillary hypercellularity (%) | 40(80 %) |
| Adhesion(%) | 25(50.0 %) |
| Cases with crescent | |
| Cellular crescent(%) | 27(54.0 %) |
| Fibrocellular crescent(%) | 26(52.0 %) |
| Fibrous crescent(%) | 26(52.0 %) |
| Interstitial inflammation change | |
| Acute-mild inflammation(%) | 8(16.0 %) |
| Acute-medium inflammation(%) | 3(6.0 %) |
| Acute-heavy inflammation(%) | 1(2.0 %) |
| Chronic-mild inflammation(%) | 5(10.0 %) |
| Chronic-medium inflammation(%) | 14(28.0 %) |
| Chronic-heavy inflammation(%) | 1(2.0 %) |
| Vasculopathy | |
| Mild-endarterium hyperplasia(%) | 16(32.0 %) |
| Medium-endarterium hyperplasia(%) | 12(24.0 %) |
| Hard-endarterium hyperplasia(%) | 3(6.0 %) |
| Hyalinosis(%) | 28(56.0 %) |
Fig. 1A: Light microscopy findings in renal biopsy: There is marked global endocapillary hypercellularity with numerous infiltrating neutrophils causing obliteration of the capillary lumina. (hematoxylin and eosin: ×200). B: Light microscopy findings in renal biopsy: There is marked global endocapillary hypercellularity and subendothelial deposits (arrow) ,mesangial deposits.(methenamine silver: ×200) C: Light microscopy findings in renal biopsy: There is marked global endocapillary hypercellularity and mesangial, “hump”-like deposits (arrow) (Masson’s trichrome: ×200) D: Light microscopy findings in renal biopsy: All glomeruli show diffuse endocapillary hypercellularity and neutrophilic infiltration, tubulointerstitial changes are mild. (periodic acid-Schiff: ×200 ) E: C3 immunostaining. There is coarsely granular glomerular staining: globally in the mesangium and segmentally in the glomerular capillary walls in the distribution of subepithelial humps ( IF: ×400). F: IgA immunostaining. There is bright, coarsely granular glomerular staining: globally in the mesangium and segmentally in the glomerular capillary walls in the distribution of subepithelial humps (arrows; IF:×400). G: Transmission electron microscopy showing subepithelial deposits (arrows), the upper deposits with hump characteristics. Also shown are scattered mesangial deposits (arrow heads) ×2000
IgA-dominant postinfectious glomerulonephritis: Immunofluorescence and Electron microscopy
| Statistical result | |
|---|---|
| Immunofluorescence | Total = 50 |
| IgA Capillary (%) | 9(18.0 %) |
| IgA Mesangium(%) | 50(100 %) |
| IgG Capillary (%) | 3(6.0 %) |
| IgG Mesangium(%) | 11(22.0 %) |
| IgM Capillary (%) | 8(16.0 %) |
| IgM Mesangium(%) | 21(42.0 %) |
| C1q Capillary (%) | 1(2.0 %) |
| C1q Mesangium(%) | 0(0.0 %) |
| C3 Capillary (%) | 11(22.0 %) |
| C3 Mesangium(%) | 46(92 %) |
| C4 Capillary (%) | 1(2.0 %) |
| C4 Mesangium(%) | 1(2.0 %) |
| Fibrinogen Capillary (%) | 5(10.0 %) |
| Fibrinogen Mesangium(%) | 10(20.0 %) |
| Kappa(%) | 32(64.0 %) |
| Lambda(%) | 42(84.0 %) |
| Electron microscopy | Total = 14 |
| Basement membrane thickening(%) | 0(0.0 %) |
| Endotheliocytosis (%) | 11(78.5 %) |
| Foot process fusion (%) | 14(100 %) |
| Mesangial hypercellularity(%) | 10(71.4 %) |
| Mesangial matrix expansion (%) | 9(64.3 %) |
| Dense deposits | |
| Mesangium (%) | 10(71.4 %) |
| Paramesangium(%) | 7(50.0 %) |
| Subepithelial (%) | 3(21.4 %) |
| Subendothelial(%) | 1(7.1 %) |
| Intramembrane(%) | 0(0.0 %) |
| Hump (%) | 1(7.1 %) |
Pathological prifiles under electron microscopy in this study
| Statistical result | |
|---|---|
| Microscopy(Electron microscopy, | |
| Basement membrane thickening(%) | 0(0.0 %) |
| Endotheliocytosis (%) | 11(78.5 %) |
| Foot process fusion (%) | 14(100 %) |
| Mesangial hypercellularity(%) | 10(71.4 %) |
| Mesangial matrix expansion (%) | 9(64.3 %) |
| Dense deposits | |
| Mesangium (%) | 10(71.4 %) |
| Paramesangium(%) | 7(50.0 %) |
| Subepithelial (%) | 3(21.4 %) |
| Subendothelial(%) | 1(7.1 %) |
| Intramembrane(%) | 0(0.0 %) |
| Hump (%) | 1(7.1 %) |
Comparision between IgA-DPIGN group and IgAN group
| IgAN | IgA-DPIGN | ||
|---|---|---|---|
| n | 150 | 50 | |
| female | 90 | 29 | |
| Age (year, mean (SD)) | 43.58 (13.40) | 42.82 (16.05) | 0.742 |
| Systolic pressure(mmHg,mean (SD)) | 132.20 (20.03) | 130.75 (19.63) | 0.671 |
| Diastolic pressure (mmHg,mean (SD)) | 79.82 (11.07) | 76.56 (10.73) | 0.085 |
| BMI (mean (SD)) | 23.26 (3.17) | 23.58 (4.24) | 0.603 |
| MBP (mmHg,mean (SD)) | 97.28 (12.42) | 94.62 (12.43) | 0.213 |
| Follow-up month (month,mean (SD)) | 24.53 (26.24) | 24.80 (25.35) | 0.95 |
| Total cholesterol (mmol/L,mean (SD)) | 4.80 (1.14) | 5.50 (1.68) | 0.001 |
| Triglyceride (mmol/L,mean (SD)) | 1.86 (1.00) | 1.66 (0.89) | 0.209 |
| HDL(mmol/L,mean (SD)) | 1.08 (0.29) | 1.19 (0.41) | 0.039 |
| LDL(mmol/L,mean (SD)) | 2.82 (0.90) | 3.22 (1.38) | 0.021 |
| Serum creatinine (mg/dL,mean (SD)) | 1.44 (1.65) | 1.39 (1.07) | 0.837 |
| Proteinuria(g/d,mean(SD)) | 1.96 (2.38) | 3.24 (3.41) | 0.004 |
| Serum albumin(g/L,mean(SD)) | 37.78 (7.38) | 32.28 (6.48) | < 0.001 |
| Uric acid(mg/dL,mean (SD)) | 5.69 (1.78) | 5.97 (1.64) | 0.056 |
| Hemoglobin (g/L,mean(SD)) | 119.73 (19.10) | 116.45 (16.65) | 0.283 |
| Fibrinogen(g/L,mean(SD)) | 3.55 (1.04) | 4.19 (1.37) | 0.001 |
| eGFR(mL/(min•1.73 m2 )mean(SD)) | 76.14 (34.75) | 73.87 (34.16) | 0.688 |
| Pathological report | |||
| M1 (%) | 63 (42.3) | 25 (50.0) | 0.432 |
| E1 (%) | 34 (22.8) | 39 (78.0) | < 0.001 |
| S1 (%) | 109 (73.2) | 33 (66.0) | 0.431 |
| Tscore (%) | 0.216 | ||
| T0 | 80 (53.7) | 21 (42.0) | |
| T1 | 38 (25.5) | 19 (38.0) | |
| T2 | 31 (20.8) | 10 (20.0) | |
| C1 (%) | 57(38.0) | 29 (58.0) | 0.005 |
| Treatment | |||
| ACEI (%) | 22 (14.7) | 1 (2.0) | 0.03 |
| ARB (%) | 79 (52.7) | 22 (44.0) | 0.369 |
| Steroid (%) | 46 (30.7) | 27 (54.0) | 0.005 |
| CTX (%) | 10 (6.7) | 6 (12.0) | 0.367 |
| otherIM (%) | 13 (8.7) | 1 (2.0) | 0.201 |
BMI body mass index, MBP mean blood pressure, HDL high density lipoprotein, LDL low density lipoprotein, eGFR estimated glomerular filtrationrate, MESTC-score the assessment of mesangial hypercellularity/endocapillary hypercelluarrity/segmental sclerosis/renal tubular lesion/crescent according to the Oxford classification, M1 mesangial hypercellularity, E1 endocapillary hypercellularity, S1 segmental glomerulosclerosis, T1/2 tubular atrophy and interstitial fibrosis > 25 %, C1 crescents in at least one glomerulus, ARB angiotensin receptor antagonist, IM immunosuppressant, CTX cyclophosphamide, ACEI angiotesin-converting enzyme, IgA-DPIGN IgA-dominant postinfectious glomerulonephritis, IgAN primary IgA nephropathy
All the data above are acquired before the renal biopsy
Fig. 2Comparison of prognosis between IgA-DPIGN group and IgAN group (Kaplan-Meier curve), p-value = 0.0013. The endpoint is that the serum creatinine level doubled of the baseline or reached end stage renal disease. IgA-DPIGN, IgA-dominant postinfectious glomerulonephritis; IgAN, primary IgA nephropathy
Cox regression analysis
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Factors | HR(95 %CI for HR) | HR(95 %CI for HR) | ||
| Age (year) | 0.99 (0.96-1.00) | 0.27 | ||
| Female | 0.42 (0.21–0.81) | 0.01 | ||
| Proteinuria (g/24-h) | 1.20 (1.10–1.40) | < 0.001 | ||
| Total cholesterol (mmol/L) | 1.40 (1.10–1.70) | 0.009 | ||
| Triglyceride (mmol/L) | 1.20 (0.84–1.70) | 0.31 | ||
| High density lipoprotein (mmol/L) | 0.83 (0.25–2.80) | 0.76 | ||
| Low density lipoprotein (mmol/L) | 1.70 (1.30–2.20) | < 0.001 | ||
| Serum creatinine (mg/dL) | 1.60 (1.40–1.90) | < 0.001 | 1.99(1.56–2.55) | < 0.001 |
| Serum albumin (g/L) | 0.91 (0.86–0.96) | 0.001 | 0.92(0.86–0.97) | 0.004 |
| Serum uric acid (mg/dL) | 1.30 (1.10–1.60) | 0.002 | 1.33(1.07–1.65) | 0.01 |
| Hemoglobin (g/L) | 0.99 (0.97-1.00) | 0.64 | ||
| Fibrinogen (g/L) | 1.30 (1.10–1.60) | 0.015 | ||
| M1 | 1.60 (0.80–3.20) | 0.19 | ||
| E1 | 2.00 (1.00-3.80) | 0.044 | ||
| S1 | 1.50 (0.63–3.60) | 0.36 | ||
| T score | ||||
| T0 | refer | - | refer | - |
| T1 | 1.20 (0.63–2.40) | 0.54 | ||
| T2 | 3.20 (1.60–6.50) | 0.002 | 2.02(0.69–5.95) | 0.20 |
| C1 | 2.30 (1.20–4.50) | 0.016 | 1.65(0.79–3.48) | 0.19 |
| IgA-DPIGN | 2.30 (1.20–4.40) | 0.016 | 3.98(1.69–9.37) | 0.002 |
| eGFR (mL/(min•1.73 m2 )) | 0.99 (0.98-1.00) | 0.01 | 1.02(1.01–1.04) | < 0.001 |
Endpoint is the increase of serum creatinine to 2 times the base line or end-stage renal diseasse. Factors that have statistical differences (p < 0.1) were sent to make the selection(Forward-backward stepwise regression method) according to the Akaike information criterion and the factors remained were selected to make multivariate analysis
HR Hazard ratio, CI confidence interval, eGFR estimated glomerular filtration rate, MESTC-score the assessment of mesangial hypercellularity/endocapillary hypercelluarrity/segmental sclerosis/renal tubular lesion/crescent according to the Oxford classification, M1 mesangial hypercellularity, E1 endocapillary hypercellularity, S1 segmental glomerulosclerosis, T1/2 tubular atrophy and interstitial fibrosis > 25 %, C1/2 crescents in at least one glomerulus, IgA-DPIGN IgA-dominant postinfectious glomerulonephritis
All the data above are acquired before the biopsy